T cell help to B cells is a critical component of adaptive humoral immunity^[@R1],\ [@R2]^. During viral infections, the formation of germinal centers (GCs) by antigen (Ag)-specific B cells requires key signals provided by T follicular helper (T~FH~) cells^[@R3]^, resulting in the development of high-affinity long-lived plasma cells and memory B cells^[@R4],\ [@R5]^. T~FH~ differentiation begins outside of B cell follicles in a stepwise fashion. Early induction of key molecules of T~FH~ differentiation, such as Bcl6, CXCR5, ICOS, and PD-1, occurs in the T cell zone when CD4^+^ T cells interact with Ag-presenting dendritic cells (DCs) or other antigen presenting cells (APCs), which then enable the migration of the activated CD4^+^ T cells towards the border of B cell follicles. Upon recognition of cognate Ag-presenting B cells, the differentiating T~FH~ cells migrate deep inside B cell follicles and further differentiate into GC T~FH~ cells as they direct the generation of GC B cells.

The requirement of repeated interactions with APCs is an important feature of T~FH~ differentiation^[@R3]^, which is presumably connected to the maintenance of the activity of critical transcription factors such as Bcl6^[@R6],\ [@R7],\ [@R8]^, Batf^[@R9]^, STAT3^[@R10],\ [@R11],\ [@R12]^, STAT1^[@R10]^, and Ascl2^[@R13]^ that support T~FH~ differentiation. Among them, Bcl6 function is absolutely critical. T~FH~ differentiation is completely abrogated in *Bcl6*^−/−^ CD4^+^ T cells^[@R6],\ [@R7],\ [@R8]^ and ectopic *Bcl6* expression in CD4^+^ T cells leads to augmented T~FH~ differentiation^[@R6],\ [@R9]^. A number of signaling molecules have been identified that can regulate Bcl6 expression in CD4^+^ T cells^[@R14]^. However, attempts to polarize CD4^+^ T cells to T~FH~ *in vitro* using IL-6 and IL-21 fail to reproducibly induce Bcl6 and CXCR5 expression. Therefore, there are clear gaps in our understanding of the molecular requirements for Bcl6 induction and the factors that support T~FH~ differentiation^[@R3]^.

LEF1-1 and TCF-1 (encoded by *Lef1* and *Tcf7*, respectively) are transcription factors that contain a conserved high mobility group (HMG) DNA binding domain. TCF-1 and LEF-1 are known for their essential roles in early T cell development, including T lineage specification and β-selection during the CD4^−^CD8^−^ double negative stage^[@R15],\ [@R16]^. TCF-1 and LEF-1 critically regulate CD4^+^ versus CD8^+^ T cell lineage commitment upon completion of positive selection of CD4^+^CD8^+^ double positive thymocytes^[@R17],\ [@R18]^. In mature CD8^+^ T cells, TCF-1 and LEF-1 regulate the generation, maturation and longevity of memory CD8^+^ T cells in response to viral or bacterial infection^[@R19],\ [@R20],\ [@R21]^. In mature CD4^+^ T cells, TCF-1 promotes T~H~2 differentiation *in vitro* via positive regulation of GATA-3^[@R22]^. TCF-1 restrains expression of interleukin 17 (IL-17A) in developing thymocytes and activated CD4^+^ T cells^[@R23]^. In addition, TCF-1 can interact with the transcription factor Foxp3 and appears to oppose Foxp3-mediated gene repression in regulatory CD4^+^ T cells^[@R24]^.

Here we looked for undiscovered regulators of early T~FH~ differentiation and found that LEF-1 and TCF-1 are critical transcriptional regulators of T~FH~ differentiation. Using a knock-in reporter system and RNA-seq analysis we found that these transcription factors were highly expressed in T~FH~ cells upon viral or bacterial infections. Genetic deletion of *Lef1*, *Tcf7*, or both factors in CD4^+^ T cells led to T~FH~ differentiation defects in a dose dependent manner. As a consequence, the magnitude of B cell responses and germinal center reactions was substantially diminished in LEF-1- and TCF-1-deficient mice after infection. Mechanistically, LEF-1 and TCF-1 regulate multiple interacting mechanisms upstream of Bcl6 to preferentially instruct activated CD4^+^ T cells to undertake T~FH~ differentiation.

RESULTS {#S1}
=======

Transcriptional profiles of early T~FH~ cells versus T~H~1 cells {#S2}
----------------------------------------------------------------

Initial CD4^+^ T cell contact with APCs in the T cell zone can promote expression of key T~FH~ molecules including Bcl6 and CXCR5. By 72 hours into an acute viral infection, the early T~FH~ and T~H~1 cells have become fate-committed^[@R25],\ [@R26]^. Early T~FH~ cells are IL-2Rα^lo^Bcl6^hi^Blimp1^−^CXCR5^hi^ , while early T~H~1 cells are IL-2Rα^+^ and Tbet^hi^Bcl6^−^Blimp1^hi^ in the context of acute viral and bacterial infections^[@R25],\ [@R26],\ [@R27],\ [@R28]^. To identify new factors important in the programming of T~FH~ cells we performed gene expression analysis on early T~FH~ and T~H~1 cells using RNA-seq. Congenically marked CD45.1^+^ Blimp1-YFP reporter LCMV-specific TCR transgenic CD4^+^ T cells (SMARTA) were transferred into B6 host mice given an acute infection with the Armstrong strain of LCMV (LCMV-Arm), and early T~FH~ and T~H~1 cells were isolated three days after infection and purified to homogeneity by sorting IL-2Rα^−^Blimp1-YFP^−^ and IL-2Rα^+^Blimp1-YFP^+^ cells, respectively. RNA-seq was performed on the isolated RNA and early T~FH~ and T~H~1 transcriptome profiles were obtained ([Fig. 1a--b](#F1){ref-type="fig"}). Analysis revealed that approximately 1,200 genes were upregulated more than 1.5 fold in early T~FH~ cells relative to T~H~1 cells, and 1,600 genes were downregulated more than 1.5 fold ([Fig. 1b](#F1){ref-type="fig"}). Early T~FH~ cells expressed many genes that are also preferentially expressed by fully differentiated T~FH~ and GC T~FH~ (*Bcl6*, *Cxcr5*, *Pdcd1*, *Pou2af1* and *Tnfsf8* among others) and had low expression of many genes repressed in fully differentiated T~FH~ and GC T~FH~ (*Prdm1*, *Tbx21*, *IL2ra*, *Gzmb* and *Prf1* among others) ([Fig. 1a, b](#F1){ref-type="fig"}). Thus, major attributes of T~FH~ and T~H~1 cells are transcriptionally well defined by day 3 of an acute viral infection.

*Lef1* is a transcriptional regulator of T~FH~ differentiation {#S3}
--------------------------------------------------------------

To further filter the 2,800 gene expression differences between early T~FH~ cells and T~H~1 cells, we focused on transcription factors. We then performed an additional set of RNA-seq experiments using i*n vitro* activated CD4^+^ T cells under T~H~1 polarizing conditions (IL-12 + αIL-4 + αTGF-β) or with IL-6 (IL-6 + αIFN-γ+αIL-12). These screening conditions were used because *in vitro* stimulation of CD4^+^ T cells in the presence of IL-6 resulted in some gene expression changes associated with T~FH~ differentiation ([Supplementary Fig. 1a--c](#SD1){ref-type="supplementary-material"}. Most notably, *Il21* was robustly induced by IL-6); however, major aspects of T~FH~ biology were not detected in IL-6-stimulated CD4^+^ T cells, such as CXCR5 protein expression and sustained Bcl6 expression^[@R3],\ [@R13],\ [@R29],\ [@R30]^ ([Supplementary Fig. 1f](#SD1){ref-type="supplementary-material"}). This outcome suggested that key transcriptional regulators required for T~FH~ differentiation are not induced under IL-6 conditions *in vitro*. We next performed a comparative analysis of gene expression differences between the *in vivo* generated early T~FH~ and the *in vitro* IL-6 stimulated CD4^+^ T cells. To reveal critical unidentified early upstream transcriptional regulators of T~FH~ differentiation we focused on genes meeting two conditions: preferential expression by early T~FH~ cells *in vivo* and lack of differential expression after *in vitro* stimulation with IL-6. *Lef1* satisfied these two conditions ([Fig. 1b](#F1){ref-type="fig"}, [Supplementary Fig. 1d, g](#SD1){ref-type="supplementary-material"}) and was selected for further analysis in part because LEF-1 is required for the formation of memory CD8^+^ T cells^[@R20]^ and there are similarities between T~FH~ and memory CD8^+^ T cell differentiation^[@R25],\ [@R31]^.

When expressed in SMARTA CD4^+^ T cells, an shRNAmir expression vector targeting *Lef1* (sh*Lef1*-RV) inhibited expression of both LEF-1 protein isoforms ([Fig. 1c](#F1){ref-type="fig"}). To test whether early T~FH~ differentiation *in vivo* is dependent on LEF-1, SMARTA CD45.1^+^ CD4^+^ T cells expressing a control shRNA (sh*Ctrl*) or sh*Lef1*^+^ SMARTA CD4^+^ T cells were transferred into B6 mice. Three days after LMCV infection of recipient mice, sh*Lef1*^+^ SMARTA CD4^+^ T cells produced approximately half the number of early T~FH~ cells compared to sh*Ctrl*^+^ SMARTA CD4^+^ T cells as assessed by flow cytometry using either Bcl6^+^CXCR5^+^ ([Fig. 1e](#F1){ref-type="fig"}) or IL2Rα^−^CXCR5^+^ ([Fig. 1f](#F1){ref-type="fig"}) phenotyping. The impact of LEF-1 knock-down was selective to T~FH~ differentiation, as SMARTA CD4^+^ T cell activation (CD44 upregulation, not shown) and proliferation ([Fig. 1d](#F1){ref-type="fig"}) were comparable between sh*Ctrl*^+^ and sh*Lef1*^+^ CD4^+^ T cells. The reduced T~FH~ differentiation by sh*Lef1*^+^ CD4^+^ T cells indicated that LEF-1 may be an important and dose limiting contributor to this process.

*Lef1* controls T~FH~ differentiation and germinal center formation {#S4}
-------------------------------------------------------------------

We next examined whether LEF-1 function in CD4^+^ T cells was important for GC T~FH~ differentiation and germinal center reactions. sh*Lef1*^+^ or sh*Ctrl*^+^ SMARTA CD4^+^ T cells were transferred into B6 mice and analyzed 8 days after acute LCMV infection of the recipient mice. Activation and proliferation of CD4^+^ T cells were not affected by reduced *Lef1* expression compared to sh*Ctrl* ([Fig. 2a](#F2){ref-type="fig"}), but T~FH~ differentiation of sh*Lef1*^+^ cells was impaired ([Fig. 2b--c](#F2){ref-type="fig"}). The sh*Lef1*^+^ T~FH~ defect was less severe than that observed on day 3, potentially due to the fact that sustained gene knock-down in CD4^+^ T cells *in vivo* is difficult to accomplish under conditions of rapid proliferation. We note that we have observed milder T~FH~ differentiation defects for most shRNAmir-RVs at peak proliferation time points compared to early time points after infection, including shRNAmir against *Bcl6* (data not shown). Nevertheless, sh*Lef1*^+^ SMARTA CD4^+^ T cells showed defective differentiation into GC T~FH~, identified here as PSGL-1^lo^CXCR5^+^ T cells ([Fig. 2d](#F2){ref-type="fig"}) or Bcl6^+^CXCR5^+^ T cells ([Fig. 2e](#F2){ref-type="fig"}), compared to sh*Ctrl*^+^ SMARTA CD4^+^ T cells. As a result, the development of GC B cells (Bcl6^+^CD19^+^) was moderately impaired in the presence of sh*Lef1*^+^ SMARTA CD4^+^ T cells as compared to sh*Ctrl*^+^ cells ([Fig. 2f](#F2){ref-type="fig"}). Taken together, reduction of LEF-1 expression in CD4^+^ T resulted in loss of T~FH~ and GC T~FH~ cells and a proportional loss of GC B cells during an immune response to LCMV.

Ablation of *Lef1* diminishes GC T~FH~ differentiation {#S5}
------------------------------------------------------

We next investigated the role of LEF-1 in T~FH~ differentiation using conditional gene-targeted *Lef1*^fl/fl^ mice. Lineage-specific deletion of *Lef1* in thymocytes with *Cd4*-Cre impairs CD4^+^ T cell lineage choice and diminishes CD4^+^ T cell output^[@R18]^. To avoid this, we used human CD2 promoter-driven Cre recombinase transgenic mice (h*CD2*-Cre), which achieve gene ablation in mature T cells^[@R32]^. Mice were also crossed to the Rosa26-STOP-GFP (*Rosa26*^GFP^) allele. As marked by GFP expression due to excision of the floxed transcription-translation STOP sequence from *Rosa26*^GFP^ allele, over 70% of splenic CD4^+^ T cells in h*CD2*-Cre *Rosa26*^GFP^ mice were GFP^+^, whereas less than 15% of CD4^+^ thymocytes were GFP^+^ ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). We crossed h*CD2*-Cre *Rosa26*^GFP^ to the *Lef1*^fl/fl^ strain to generate h*CD2*-Cre *Rosa26*^GFP^*Lef1*^fl/fl^ mice (called *Lef1*^−/−^ hereafter). Both isoforms of LEF-1 were completed ablated in GFP^+^ CD4^+^ T cells from *Lef1*^−/−^ mice ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). Late deletion of LEF-1 did not detectably affect thymocyte development or cause aberrant activation of mature T cells ([Supplementary Fig. 2d, f, h, i](#SD1){ref-type="supplementary-material"}) but reduced total thymic cellularity by approximately 15% and mature CD4^+^ T cells by approximately 25% ([Supplementary Fig. 2e, g](#SD1){ref-type="supplementary-material"}). To determine the impact of LEF-1 deficiency in CD4^+^ T cells on T~FH~ differentiation, we infected *Lef1*^−/−^ mice and littermate controls (h*CD2*-Cre^−^*Lef1*^+/fl^ or h*CD2*-Cre^+^*Lef1*^+/+^) with vaccinia virus and assessed the presence of CD44^hi^CD62L^−^ activated GFP^+^ CD4^+^ splenic T cells on day 8 post infection. The frequency of T~H~1 cells (SLAM^hi^CXCR5^−^) were similar in *Lef1*^−/−^ mice and littermate control mice, though the absolute numbers of SLAM^hi^CXCR5^−^ T~H~1 cell were modestly decreased compared to control (p = 0.51, [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), consistent with a modestly reduced CD4^+^ T cell compartment in uninfected *Lef1*^−/−^ mice ([Supplementary Fig. 2g](#SD1){ref-type="supplementary-material"}). SLAM^−^CXCR5^+^ T~FH~ cell numbers were more markedly decreased in the vaccinia virus-immunized *Lef1*^−/−^ mice compared to littermate controls (p = 0.006, [Fig. 3a](#F3){ref-type="fig"}). In particular, the number of GC T~FH~ cells were diminished to a much greater extent in *Lef1*^−/−^ mice compared to littermate controls (Bcl6^+^CXCR5^+^ and PD-1^hi^CXCR5^+^ phenotyping [Fig. 3b,c](#F3){ref-type="fig"}). These data further corroborate a role of LEF-1 in directing T~FH~ differentiation.

TCF-1 expression is retained in T~FH~ but not T~H~1 cells {#S6}
---------------------------------------------------------

RNA-seq analysis of early T~FH~ and T~H~1 cells isolated from B6 mice revealed that *Tcf7* was also strongly expressed by early T~FH~ cells, but *Tcf7* was not induced by *in vitro* stimulation of CD4^+^ T cells with IL-6 ([Fig. 1b](#F1){ref-type="fig"}, [Supplementary Fig. 1e, g](#SD1){ref-type="supplementary-material"}). Given that LEF-1 and TCF-1 are related transcription factors, we investigated whether TCF-1 was also an early regulator of T~FH~ differentiation. For this purpose, we generated *Tcf7*-GFP knock-in mice (called *Tcf7*^GFP^ here, [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). The *Tcf7*-GFP reporter was abundantly expressed in CD4^+^ and CD8^+^ T cells and CD4^+^CD25^+^ regulatory T cells but was absent in B220^+^ cells, demonstrating the reporter fidelity ([Supplementary Fig. 4b--d](#SD1){ref-type="supplementary-material"}). The expression of *Tcf7*-GFP was highest in CD44^lo^CD62L^+^ naïve T cells but was low in antigen-experienced T cell subsets such as CD44^hi^CD62L^+^ memory-phenotype T cells, and particularly CD44^hi^CD62L^−^ effector-phenotype T cells ([Supplementary Fig. 4b, c](#SD1){ref-type="supplementary-material"}). To analyze TCF-1 expression kinetics in antigen-specific CD4^+^ T cells we generated *Tcf7*^GFP/+^ SMARTA mice and adoptively transferred naïve CD44^lo^CD62L^+^ SMARTA CD45.2^+^ CD4^+^ T cells into CD45.1^+^ congenic recipients. Following LCMV infection, *Tcf7*-GFP expression was greatly diminished in SLAM^hi^ CXCR5^−^ T~H~1 cells by day 8 post-infection compared to naive CD4 T cells, while *Tcf7*-GFP expression was maintained at a high level by most SLAM^lo^CXCR5^+^ T~FH~ cells ([Fig. 4a](#F4){ref-type="fig"}).

We next investigated if the retention of TCF-1 expression was associated with the T~FH~ differentiation program in response to other *in vivo* stimuli. Following adoptive transfer of *Tcf7*^GFP^ SMARTA CD4^+^ T cells, we infected recipient mice with *Listeria monocytogenes* expressing the GP61 epitope of LCMV. In other experiments, we directly infected *Tcf7*^GFP/+^ mice with vaccinia virus, as a second viral infection model. Whereas SLAM^hi^CXCR5^−^ T~H~1 cells that developed in both systems preferentially downregulated *Tcf7*-GFP expression, SLAM^lo^CXCR5^+^ T~FH~ cells generated in response to both the bacterial and viral infections highly retained *Tcf7*-GFP expression ([Supplementary Fig. 4e, f](#SD1){ref-type="supplementary-material"}). Considering that TCF-1 is known to be markedly downregulated in effector CD8^+^ T cells^[@R33]^, these observations indicate that retention of TCF-1 expression at the effector phase of a T cell response is unique to T~FH~ cells, and further suggest a possible requirement for TCF-1 in T~FH~ differentiation.

Both LEF-1 and TCF-1 are essential for T~FH~ responses {#S7}
------------------------------------------------------

To address the role of TCF-1 in T~FH~ cells, we generated h*CD2*-Cre *Rosa26*^GFP^*Tcf7^fl/fl^* mice (called *Tcf7*^−/−^ hereafter), where all isoforms of TCF-1 were ablated from GFP^+^ CD4^+^ T cells ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). To investigate the functional redundancy between LEF-1 and TCF-1 we also crossed *Tcf7*^−/−^ with *Lef1*^−/−^ mice to generate *Lef1*^−/−^*Tcf7*^−/−^ mice (h*CD2*-Cre *Rosa26*^GFP^ *Lef1*^fl/fl^*Tcf7*^fl/fl^). Similar to the *Lef1*^−/−^ mice, we did not observe T cell development defects or aberrant activation of mature T cells in *Tcf7*^−/−^ mice or *Lef1*^−/−^*Tcf7*^−/−^ mice ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Although a modest reduction in thymic and splenic cellularity was observed in *Tcf7*^−/−^ mice, this was not evident in *Lef1*^−/−^*Tcf7*^−/−^ mice compared to littermate controls (h*CD2*-Cre^−^*Lef1*^+/fl^*Tcf7*^+/fl^ or h*CD2*-Cre^+^*Lef1*^+/+^*Tcf7*^+/+^) ([Supplementary Fig. 2d, f, h, i](#SD1){ref-type="supplementary-material"}). We examined the CD4^+^ T cell responses of the *Lef1*^−/−^*Tcf7*^−/−^ mice in response to vaccinia virus infection. On day 8 after infection, analysis of CD44^hi^CD62L^−^ activated GFP^+^ CD4^+^ T cells revealed that the frequencies and numbers of SLAM^lo^CXCR5^+^ T~FH~ cells were diminished in *Tcf7*^−/−^ mice compared to control mice ([Fig. 4b](#F4){ref-type="fig"}), with comparable reduction of GC T~FH~ cells (Bcl6^+^CXCR5^+^ and PD-1^hi^CXCR5^+^ phenotyping, [Fig. 4c,d](#F4){ref-type="fig"}). We found stronger defects in *Lef1*^−/−^*Tcf7*^−/−^ mice compared to *Tcf7*^−/−^ mice ([Fig. 4b-4d](#F4){ref-type="fig"}), indicating that both LEF-1 and TCF-1 contribute to regulation of T~FH~ differentiation.

Consistent with the observations above, *Tcf7*^−/−^ and *Lef1*^−/−^*Tcf7*^−/−^ mice exhibited significantly diminished frequency and numbers of GL7^+^Fas^+^ GC B cells compared to control mice ([Fig. 4e](#F4){ref-type="fig"}), with the most severe GC B cell defect in *Lef1*^−/−^*Tcf7*^−/−^ mice ([Fig. 4e](#F4){ref-type="fig"}). The number of IgD^lo^CD138^+^ plasma cells was moderately reduced in *Tcf7*^−/−^ mice, but severely compromised in *Lef1*^−/−^*Tcf7*^−/−^ mice ([Fig. 4f](#F4){ref-type="fig"}). As a result, vaccinia virus-specific Ab production was significantly impaired in *Lef1*^−/−^*Tcf7*^−/−^ mice compared to controls ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). In summary, our data indicate that LEF-1 and TCF-1 play critical roles in T~FH~ differentiation and, consequently, B cell help functions in a CD4^+^ T cell intrinsic manner.

Ectopic *Lef1* expression augments T~FH~ differentiation {#S8}
--------------------------------------------------------

We next tested whether enhanced expression of one of these transcription factors could augment T~FH~ differentiation of antigen-specific CD4^+^ T cells. Given that LEF-1 and TCF-1 exhibited overlapping activities instructing T~FH~ differentiation, we examined T~FH~ differentiation of CD4^+^ T cells after ectopic expression of LEF-1. LEF-1 can be expressed as two isoforms in CD4^+^ T cells due to differential promoter usage ([Fig. 1c](#F1){ref-type="fig"}), with the full-length isoform containing a unique N-terminal β-catenin-binding domain. We used a retrovirus expressing the full-length *Lef1* (*Lef1*-RV^+^) and confirmed increased expression of LEF-1 protein in *Lef1*-RV^+^ SMARTA CD45.1^+^ CD4^+^ T cells by flow cytometry ([Fig. 5a](#F5){ref-type="fig"}) and immunoblot analysis (data not shown). GFP-RV^+^ or *Lef1*-RV^+^ CD45.1^+^ SMARTA CD4^+^ T cells were transferred into B6 mice, which were then infected with LCMV. The overall activation and proliferation of *Lef1*-RV^+^ CD4^+^ T cells was normal compared to GFP-RV^+^ CD4^+^ T cells ([Fig. 5b](#F5){ref-type="fig"} and data not shown). Ectopic LEF-1 expression resulted in enhanced T~FH~ development by *Lef1*-RV^+^ cells compared to GFP-RV^+^ cells 8 days post-infection ([Fig. 5c](#F5){ref-type="fig"}). Moreover, we found that *Lef1*-RV^+^ T~H~1 cells (SLAM^hi^CXCR5^−^) exhibited unexpectedly increased expression of canonical T~FH~ molecules CXCR5 ([Fig. 5d](#F5){ref-type="fig"}) and PD-1 ([Fig. 5e](#F5){ref-type="fig"}) compared to GFP-RV^+^ cells. Most importantly, GC T~FH~ cells (phenotyped as either PSGL-1^lo^CXCR5^+^ or PD-1^hi^CXCR5^+^ cells [Fig. 5f, g](#F5){ref-type="fig"}) developed at significantly higher frequencies among *Lef1*-RV^+^ SMARTA CD4^+^ T cells compared to GFP-RV^+^ control cells.

LEF-1 enhances expression of IL-6 receptors and ICOS {#S9}
----------------------------------------------------

To gain insights into how LEF-1 regulates T~FH~ differentiation, we performed RNA-seq on GFP-RV^+^ or *Lef1*-RV^+^ CXCR5^lo^ T~H~1 and CXCR5^hi^ T~FH~ SMARTA CD4^+^ T cells. We next used transcriptional signatures of T~FH~ and GC T~FH~ cells (see Methods) and Gene Set Enrichment Analysis (GSEA) to investigate whether these gene expression signatures were enriched in *Lef1*-RV^+^ T~H~1 cells in comparison to control T~H~1 cells (GFP-RV^+^). We found substantial enrichment of the T~FH~ and GC T~FH~ gene signatures ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) in T~H~1 cells constitutively expressing *Lef1* (NES = 1.21, T~FH~ GSEA; NES = 1.29, GC T~FH~ GSEA, [Fig. 6a](#F6){ref-type="fig"}) compared to control T~H~1 cells. Detailed examination revealed that differential expression of *Il6rα*, *Il6st*, *Bcl6*, *Cxcr5*, *Slamf6*, and *Pou2af1* were particularly notable in the *Lef1*-RV^+^ T~H~1 cells compared to GFP-RV^+^ T~H~1 cells ([Fig. 6b](#F6){ref-type="fig"}).

Considering the induction of both IL-6 receptor genes *Il6rα* and *Il6st* in *Lef1*-RV^+^ T~H~1 cells and the fact that IL-6 receptor signaling is one of the earliest signals that instructs T~FH~ cell differentiation^[@R3]^, we tested whether LEF-1-augmented T~FH~ differentiation may be mediated through enhanced surface expression of IL-6Rα and gp130 (also known as IL-6Rβ, encoded by *Il6st*). We analyzed the expression of IL-6Rα and gp130 on the surface of *Lef1*-RV^+^ and GFP-RV^+^ SMARTA CD4^+^ T cells at day 3 after infection with LCMV, a time when IL-6 receptor signaling is known to be critical for T~FH~ differentiation^[@R10]^. Ectopic expression of LEF-1 in *Lef1*-RV^+^ SMARTA CD4^+^ T cells resulted in increased expression of IL-6Rα compared to GFP-RV^+^ SMARTA CD4^+^ T cells ([Fig. 6c](#F6){ref-type="fig"}). When comparing IL-6Rα expression between naïve CD4^+^ T cells and activated *Lef1*-RV^+^ and GFP-RV^+^ SMARTA CD4^+^ T cells, LEF-1 overexpression reduced the downregulation of IL-6Rα observed in activated GFP-RV^+^ CD4^+^ T cells ([Fig. 6c](#F6){ref-type="fig"}). LEF-1 overexpression had similar effects on gp130, reducing the downregulation of gp130 observed in activated GFP-RV^+^ CD4^+^ T cells ([Fig. 6d](#F6){ref-type="fig"}). We then examined the expression of IL-6Rα and gp130 on T~FH~ and T~H~1 subpopulations. A modest increase in IL-6Rα expression was observed on T~FH~ cells, whereas *Lef1*-RV^+^ T~H~1 cells expressed \>150% more IL-6Rα compared to GFP-RV^+^ T~H~1 cells ([Fig. 6e](#F6){ref-type="fig"}). While the expression of gp130 was only moderately increased in total *Lef1*-RV^+^ SMARTA CD4^+^ T cells compared to GFP-RV^+^ SMARTA CD4^+^ T cells ([Fig. 6d](#F6){ref-type="fig"}), gp130 was preferentially upregulated on *Lef1*-RV^+^ T~H~1 cells compared to GFP-RV^+^ T~H~1 cells ([Fig. 6f](#F6){ref-type="fig"}).

RNA-seq also revealed that *Icos* expression was upregulated on *Lef1*-RV^+^ T~H~1 cells compared to GFP-RV^+^ T~H~1 cells ([Fig. 6b](#F6){ref-type="fig"}). Because ICOS plays essential roles during both early and late stages of T~FH~ differentiation^[@R26]^, we further examined ICOS expression. ICOS protein was increased in *Lef1*-RV^+^ T cells compared to GFP-RV^+^ cells ([Fig. 6g](#F6){ref-type="fig"}), and its upregulation occurred predominantly on *Lef1*-RV^+^ T~H~1 cells ([Fig. 6h](#F6){ref-type="fig"}), to levels comparable to GFP-RV^+^ T~FH~ cells. These observations indicate that LEF-1 functions to help CD4^+^ T cells retain surface expression of IL-6 receptors and upregulate ICOS expression to enhance responsiveness of activated CD4^+^ T cells to IL-6 and ICOS-L signals, two essential signals for early T~FH~ differentiation.

We then asked whether overexpression of LEF-1 could rescue T~FH~ differentiation in the absence of Bcl6. *Cd4*-Cre *Bcl6*^fl/fl^ CD4^+^ T cells fail to differentiate into T~FH~ cells during acute viral infections or protein immunizations^[@R34]^. *Lef1*-RV^+^ or GFP-RV^+^ *Cd4*-Cre *Bcl6*^fl/fl^ SMARTA CD4^+^ T cells transferred into B6 mice failed to differentiate into T~FH~ cells *in vivo* at day 8 after LCMV infection of the recipient mice ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). These results indicate that LEF-1-mediated regulation of IL-6 receptor complex and ICOS expression act upstream of Bcl6 expression early in T~FH~ differentiation.

*Lef1*^−/−^ *Tcf7*^−/−^ GC T~FH~ cells have extensive gene regulation defects {#S10}
-----------------------------------------------------------------------------

We further assessed the requirements of LEF-1 and TCF-1 for expression of key T~FH~ molecules by transcriptomic analysis of *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells. RNA-seq was performed using total RNA extracted from GC T~FH~ cells (sorted as PD-1^hi^CXCR5^+^ of CD44^hi^CD62L^lo^GFP^+^CD4^+^ T cells) isolated from *Lef1*^−/−^*Tcf7*^−/−^ and control mice (h*CD2*-Cre^−^*Lef1*^+/fl^*Tcf7*^+/fl^ or h*CD2*-Cre^+^*Lef1*^+/+^*Tcf7*^+/+^) on day 8 after vaccinia virus infection. 306 genes were downregulated and 668 genes upregulated in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells in comparison to control GC T~FH~ cells (FDR \< 0.01 and fold change ≥ 1.5, [Fig. 7a](#F7){ref-type="fig"}). In line with the enhanced *Il6st* and *Icos* expression induced by overexpression of LEF-1, *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells had greatly reduced *Il6st* and *Icos* transcripts compared to control cells ([Fig. 7b](#F7){ref-type="fig"}). Flow cytometry showed decreased expression of gp130 and ICOS protein on *Lef1*^−/−^*Tcf7*^−/−^ CXCR5^+^ T~FH~ cells compared to T~FH~ cells from controls ([Fig. 7c and 7d](#F7){ref-type="fig"}). Although the decrease of *Il6ra* mRNA in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells did not reach statistical significance in the transcriptomic analysis, IL-6Rα protein expression was consistently reduced on *Lef1*^−/−^*Tcf7*^−/−^ CXCR5^+^ T~FH~ cells compared to T~FH~ cells from control mice (P \< 0.001, [Fig. 7e](#F7){ref-type="fig"}). These observations indicate essential and overlapping roles of both LEF-1 and TCF-1 in supporting IL-6 receptor and ICOS expression during T~FH~ differentiation.

The amount of *Bcl6* transcripts was diminished in PD-1^hi^CXCR5^+^ GC T~FH~ cells from *Lef1*^−/−^*Tcf7*^−/−^ mice compared to those from control mice ([Fig. 7b](#F7){ref-type="fig"}), while the expression of *Prdm1*, which encodes the transcription factor Blimp1, was substantially elevated in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells ([Fig. 7b](#F7){ref-type="fig"}). Bcl6 and Blimp1 are known to have mutually antagonistic roles during differentiation of T~FH~ cells^[@R6]^. Blimp1 directly inhibits Bcl6 expression and is a potent inhibitor of T~FH~ differentiation^[@R6],\ [@R28],\ [@R30]^. We validated the increased expression of *Prdm1* in *Lef1*^−/−^*Tcf7*^−/−^ PD-1^hi^CXCR5^+^ GC T~FH~ by qPCR ([Fig. 7f](#F7){ref-type="fig"}). This increase was specific to GC T~FH~ (PD-1^hi^CXCR5^+^) and T~FH~ (PD-1^lo^CXCR5^+^) cells because T~H~1 cells (CXCR5^−^) from both *Lef1*^−/−^*Tcf7*^−/−^ and control mice expressed comparable levels of *Prdm1* ([Fig. 7f](#F7){ref-type="fig"}). The transcription factor Ascl2 was shown to be important in T~FH~ differentiation^[@R13]^. *Ascl2* expression was reduced in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells, but the reduction was less pronounced in PD-1^lo^CXCR5^+^ T~FH~ cells compared to controls ([Fig. 7f](#F7){ref-type="fig"}). *Rorc* (encoding RORγt) and *Il17a* were virtually absent in control GC T~FH~ cells, but these genes were expressed in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells ([Fig. 7b](#F7){ref-type="fig"}). Although Th17 gene expression is not normally observed in vaccinia virus infection, these observations are in line with the known role of TCF-1 in restraining Th17 differentiation^[@R23]^ and indicate that LEF-1 and TCF-1 could suppress alternative T~H~ cell fates during T~FH~ differentiation, perhaps in conjunction with Bcl6, which is also known to suppress alternative cell fates^[@R3]^. Other transcriptional changes observed in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells compared to control GC T~FH~ cells included the differential expression of POU family transcription factors (decreased expression of *Pou2af1* and *Pou6f1*, and increased expression of *Pou3f1* and *Pou5f1*) and key molecules in the Notch pathway (decreased expression of *Hes5* and *Psen2*, and increased expression of *Rbpj*). The role of these factors in T~FH~ cells remains to be investigated. Overall, these observations suggest that LEF-1 and TCF-1 contribute to regulation of many genes in activated, antigen-specific CD4^+^ T cells *in vivo*, including the positive regulation of Bcl6 and repression of Blimp1 to induce T~FH~ differentiation.

TCF-1 binds directly to key T~FH~-associated gene loci {#S11}
------------------------------------------------------

We used chromatin immunoprecipitation (ChIP) to assess if LEF-1 and TCF-1 directly regulate the differentially expressed genes identified above. Both TCF-1 and LEF-1 have a highly homologous HMG DNA binding domain which recognizes the same DNA consensus motif. Because TCF-1 ChIP reagents are of substantially higher quality than currently available LEF-1 reagents, we focused on identifying TCF-1 bound genes in T~FH~ cells. Because most T~FH~ cells retained TCF-1 expression similar to naïve CD4^+^ T cells ([Fig. 4a](#F4){ref-type="fig"}), we used our TCF-1 ChIP-seq data from naïve wild-type CD4^+^ T cells (unpublished) as a reference for selection of potential TCF-1 DNA binding sites. TCF-1 enrichment was observed at the transcription start site (TSS) of *IL6st*, the TSS of *Bcl6*, a −2.8kb region upstream of *Bcl6* TSS and intron 3 of *Prdm1* in naïve CD4^+^ T cells, but was not associated with the *Il6ra* and *Ascl2* genes ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). We then performed TCF-1 ChIP using wild-type and *Tcf7*^−/−^ naïve CD4^+^ T cells to ensure binding specificity. As a positive control, TCF-1 bound to the TSS of *Axin2*, a well characterized TCF-1 responsive gene^[@R15]^, in wild-type naïve CD4^+^ T cells, and this was completely abrogated in *Tcf7*^−/−^ naïve CD4^+^ T cells ([Fig. 8a](#F8){ref-type="fig"}). In addition, TCF-1 binding to *Axin2* was enriched in T~FH~ cells (CXCR5^+^) over T~H~1 cells (CXCR5^−^) from B6 mice infected with vaccinia virus ([Fig. 8a](#F8){ref-type="fig"}), consistent with increased expression of TCF-1 protein in T~FH~ cells. TCF-1 bound to the *Il6st* gene in wild-type naïve CD4^+^ T cells ([Fig. 8b](#F8){ref-type="fig"}, right), and this was also enriched in T~FH~ cells ([Fig. 8b](#F8){ref-type="fig"}). Although TCF-1 did not bind the *Il6ra* gene in wild-type naïve CD4^+^ T cells, it was recruited to the *Il6ra* TSS in wild-type T~FH~ cells ([Fig. 8b](#F8){ref-type="fig"}, left), suggesting TCF-1 recruitment to this site is part of the T~FH~ differentiation program. Compared to naïve CD4^+^ T cells, TCF-1 did not exhibit enriched binding at *Il6st* or *Il6ra* locus in wild-type T~H~1 cells, in line with diminished expression of both IL-6Rα and gp130 in T~H~1 cells ([Fig. 7c, e](#F7){ref-type="fig"}). TCF-1 binding to the transcription start site of *Icos* was not detected ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}) These data suggest that TCF-1 directly regulates the induction of IL-6 receptor chains to sustain IL-6 receptor complex expression by activated CD4^+^ T cells *in vivo*, allowing for T~FH~ differentiation ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}).

We next examined ChIP association between TCF-1 and key transcription factor genes for T~FH~ differentiation. TCF-1 bound to intron 3 of the *Prdm1* gene, the major regulatory site of *Prdm1* expression^[@R35]^, in both naïve CD4^+^ T cells and CXCR5^+^ T~FH~ cells ([Fig. 8d](#F8){ref-type="fig"}), suggesting a direct involvement of TCF-1 and its homologue LEF-1 in Blimp1 suppression in T~FH~ cells. Given that *Prdm1* is not expressed by naïve CD4^+^ T cells, binding of TCF-1 at this site suggests that TCF-1 may antagonize *Prdm1* expression upon T cell activation. In addition, we observed specific binding of TCF-1 to the TSS of *Bcl6* and an upstream regulatory region of *Bcl6* in naive CD4^+^ T cells ([Fig. 8c](#F8){ref-type="fig"}) and this binding pattern was maintained in T~FH~ cells ([Fig. 8c](#F8){ref-type="fig"}). Robust enrichment of TCF-1 was observed in the *Prdm1*, *Bcl6*, *Il6ra*, and *Il6st* gene loci in wild-type T~FH~ cells compared to *Tcf7*^−/−^ T~FH~ cells ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}). We did not observe enriched TCF-1 binding in the *Ascl2* TSS ([Fig. 8c--d](#F8){ref-type="fig"}), albeit we could not exclude the possibility that *Ascl2* is regulated by LEF-1 and TCF-1 through more distal regulatory regions. TCF-1 binding to the *Bcl6* upstream region and *Prdm1* intron was abrogated in T~H~1 cells as compared to T~FH~ ([Fig. 8d](#F8){ref-type="fig"}), in line with the greatly reduced expression of TCF-1 in T~H~1 cells. These observations suggest that downregulation of TCF-1 in T~H~1 cells is important for upregulation of Blimp1 and Blimp1-mediated repression of Bcl6 in T~H~1 cells, while retention of TCF-1 in early T~FH~ cells ensures proper upregulation of Bcl6 and subsequent suppression of Blimp1 during T~FH~ differentiation ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#S12}
==========

T~FH~ differentiation can be initiated at an early time point during T cell activation, but the regulators of this important decision process are still being defined. Here we initiated an investigation to identify novel pathways in T~FH~ differentiation by characterizing genes differentially expressed in early T~FH~ *in vivo* but not modulated by supplementing IL-6 *in vitro*. We show that the pair of transcription factors LEF-1 and TCF-1 influence T~FH~ differentiation by regulating circuits upstream of Bcl6. We found that LEF-1 and TCF-1 coordinate T~FH~ differentiation by two general mechanisms. First, they establish the responsiveness of naïve CD4^+^ T cells to T~FH~ signals by promoting expression of IL-6 receptor chains and binding to *Prdm1* and *Bcl6*. Second, they promote early T~FH~ differentiation of activated CD4^+^ T cells via multipronged activities sustaining expression of IL-6Rα and gp130, enhancing ICOS expression and promoting expression of Bcl6 while inhibiting Blimp1 expression.

IL-6 is a critical early regulator of T~FH~ differentiation, as *Il6*^−/−^ mice fail to have any T~FH~ cell differentiation during the DC priming phase of an acute antiviral immune response^[@R10]^. In mice whose DCs constitutively overexpress IL-6, the major phenotype observed is a dramatic increase in T~FH~ cell and germinal centers^[@R36]^. Therefore, regulation of IL-6 receptor expression on naive CD4^+^ T cells and early activated CD4^+^ T cells is a clear mechanism by which LEF-1 and TCF-1 will influence T~FH~ differentiation.

Bcl6 is essential for T~FH~ differentiation, while Blimp1 is a powerful antagonist of T~FH~ differentiation. Our observations that expression of LEF-1 results in aberrant expression of Bcl6 in T~H~1 cells, Blimp1 expression is aberrantly upregulated in *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells, and both *Bcl6* and *Prdm1* are directly bound TCF-1 targets indicate that LEF-1 and TCF-1 likely dually regulate both of these critical transcription factors. While we cannot rule out the possibility that the de-repression of *Prdm1* results from reduced Bcl6 expression in *Lef1*^−/−^*Tcf7*^−/−^ T~FH~ and GC T~FH~ cells, we speculate that LEF-1 and TCF-1 directly repress *Prdm1* expression. LEF-1 and TCF-1 are known to positively and negatively regulate gene expression, depending on the interacting factors. For examples, both proteins can interact with β-catenin coactivator and TLE corepressors, and LEF-1 and TCF-1 repress *Cd4* in CD8^+^ T cells^[@R18]^. Future analysis of molecular mechanisms by which LEF-1 and TCF-1 regulate *Prdm1* and *Bcl6* genes will be important, as will analysis of how LEF-1 and TCF-1 interact with other regulators of *Bcl6* and *Prdm1*, such as STAT1, STAT3, STAT5, Foxo1, and Klf2^[@R3],\ [@R10],\ [@R11],\ [@R28],\ [@R37],\ [@R38]^. Nevertheless, our data provide proof that LEF-1 and TCF-1 regulate the balance between Bcl6 and Blimp1 expression.

ICOS expression was selectively impaired on *Lef1*^−/−^*Tcf7*^−/−^ T~FH~ cells, and ICOS expression was enhanced on *Lef1*-RV^+^ cells. In multiple models, moderate ICOS changes have been observed to enhance T~FH~ differentiation^[@R38],\ [@R39],\ [@R40],\ [@R41]^ or function^[@R42]^. ICOS appears not to be a direct target of LEF-1 and TCF-1, though distal *cis*-elements were not explored. Alternatively, ICOS may be indirectly regulated by LEF-1 and TCF-1. Future studies will further elucidate LEF-1 and TCF-1 signaling axes modulating ICOS expression. Overall, the combined influence of LEF-1 and TCF-1 on IL-6Rα, gp130, Bcl6, Blimp1, and ICOS makes a dense network of interactions that create a strong pro-T~FH~ signaling environment in a cell sustaining LEF-1 and/or TCF-1 expression.

LEF-1 and TCF-1 functions likely continue to be important in fully differentiated T~FH~ and GC T~FH~ cells. LEF-1 and TCF-1 both continue to be expressed in GC T~FH~ cells. Bcl6 expression is essential in GC T~FH~ cells^[@R3]^ and continued regulation of both *Bcl6* and *Prdm1* are central aspects of GC T~FH~ biology. ICOS is also a major regulator of GC T~FH~ biology^[@R26],\ [@R40]^. IL-6 receptor signaling is not usually essential in GC T~FH~ cells due to compensatory capabilities of IL-21 or IL-27 at later time points^[@R29],\ [@R43],\ [@R44]^. Nevertheless, IL-6 receptor likely plays a major role in sustaining GC T~FH~ under normal physiological conditions. IL-6 is required for sustaining T~FH~ and GC responses in chronic LCMV infection in mice^[@R45]^, and IL-6 is positively associated with T~FH~ cells and GCs in SIV^+^ macaques^[@R46]^.

The activities of LEF-1 and TCF-1 appear to pre-program the responsiveness of a given naive CD4^+^ T cell to T~FH~ signals, prior to any exposure of the cell to antigen. Therefore, we speculate that transient or sustained inflammatory or pathogenic conditions that alter LEF-1 or TCF-1 expression in naive T cells may have a global impact altering the capacity of naive CD4^+^ T cells to respond to T~FH~ induction signals in the presence of pathogens or autoimmunity triggers. Ultimately, it will be useful to determine how homeostatic signals act in concert with LEF-1 and TCF-1 to modulate the expression or poised status of T~FH~-associated genes in naïve CD4^+^ T cells to properly orchestrate the development progression from naive cell to T~FH~ or non-T~FH~ cell fates.

LEF-1 and TCF-1 are highly expressed in resting naive CD4^+^ and CD8^+^ T cells, but TCF-1 and LEF-1 are downregulated in effector CD8^+^ T cells and T~H~1 cells, suggesting *Lef1* and *Tcf7* are regulated by T cell activation. TCR dwell time influences T~FH~ versus non-T~FH~ differentiation in a TCR signal strength intrinsic manner^[@R47]^. We speculate these processes may be interrelated.

In conclusion, our study discovers novel roles for LEF-1 and TCF-1 in T~FH~ differentiation. Thus, a better understanding of the signals regulating LEF-1 and TCF-1 and their downstream targets in activated CD4^+^ T cells will have implications for understanding how to enhance T~FH~ differentiation, as well as for understanding non-T~FH~ CD4^+^ T cell differentiation processes.

METHODS {#S13}
=======

Mice and viral infections {#S14}
-------------------------

C57BL/6J (B6), B6.SJL, *Cd4*-Cre, and *Rosa26*^GFP^ mice were purchased from the Jackson Laboratory. Mouse strains described below were obtained from in-house breeders of either LJI or University of Iowa animal facility. SMARTA (LCMV gp66-77-IA^b^ specific) TCR transgenic mice^[@R48]^, *Tcf7*^fl/fl^ and *Lef1*^fl/fl^ mice were described^[@R16],\ [@R18]^. *Bcl6*^fl/fl^ mice and h*CD2*-Cre mice were from Drs. Toshitada Takemori^[@R49]^ and Paul Love^[@R32]^, respectively. Blimp1-YFP BAC transgenic mice were crossed to the SMARTA strain to generate Blimp1-YFP SMARTA mice^[@R26]^. *Tcf7*-GFP reporter mice were generated in house, and detailed targeting strategy and characterization will be published elsewhere (manuscript in review). All animals were analyzed at 6--12 weeks of age, and both genders included without randomization or "blinding". All mouse experiments were performed under protocols approved by the Institutional Animal Use and Care Committees of LJI and the University of Iowa. For acute viral infection, 2.5 -- 5.0 × 10^5^ plaque-forming units (PFU) and 2.5 × 10^5^ PFU was used for LCMV Armstrong (LCMV-Arm) and vaccinia virus, respectively. Virus was prepared in plain DMEM and injected intraperitoneally or intravenously.

Flow cytometry {#S15}
--------------

Single cell suspension was prepared from the spleen of mice infected with LCMV or vaccinia virus, and surface-stained as previously described^[@R16],\ [@R26]^. The fluorochrome-conjugated antibodies and their clone numbers are CD4 (RM4-5), CD44 (IM7), CD62L (MEL-14), PD-1 (J43), IL-6Rα (D7715A7), gp130 (KGP130), ICOS (C398.4A), Fas (15A7), GL7 (GL7), IgD (11--26), CD138 (281-2), Bcl6 (K112-91), and all were from eBiosciences. SLAM (TC15-12F12.2) was from BioLegend. PSGL-1 (2PH1) was from BD Biosciences. For detection of CXCR5, a two-step^[@R26]^ or three-step^[@R6]^ staining protocol was used with biotinylated anti-CXCR5 or unconjugated anti-CXCR5 Abs, respectively (2G8 from BD Biosciences). For intracellular detection of Bcl6, the surface-stained cells were fixed and permeabilized with the Foxp3/transcription factor staining buffer (eBiosciences), followed by incubation with fluorochrome-conjugated Bcl6 antibody. Data were collected on LSRII and FACSVerse (BD Biosciences) and analyzed with FlowJo software (TreeStar).

Immunoblot {#S16}
----------

For analysis of knockdown of LEF-1 or targeted deletion of TCF-1 and LEF-1, sh*Ctrl* and sh*Lef1* SMARTA cells or CD4^+^ and CD8^+^ T cells (5 × 10^5^ each) were sorted, and denatured in SDS Loading Buffer at 100°C for 5 minutes. Cell lysates were probed with anti-TCF-1 (C46C7; Cell Signaling Technology), anti-LEF-1 (C18A7 and C12A5; Cell Signaling Technology) or anti-β-actin (loading control; I-19; Santa Cruz Biotechnology).

Retroviral transductions {#S17}
------------------------

Naïve SMARTA CD4^+^ T cells were purified by negative selection using either magnetic beads (Miltenyi Biotec) or EasySep kit (STEMCELL), and resuspended in D-10 \[DMEM + 10% FCS (fetal calf serum) + 2 mM GlutaMax (Life Technologies) + 100 U/ml Penicillin/Streptomycin (Life Technologies) + 50 µM β-mercaptoethanol\] with 2 ng/ml hIL-7 or 10 ng/ml hIL-2 (Peprotech). 2 × 10^6^ SMARTA cells were seeded in 24-well plates coated with 8 µg/ml anti-CD3 (clone 17A2, BioXcell) and anti-CD28 (clone 37.51, BioXcell). Retroviral soups were given at 24 and 36 hours after stimulation. After 72 hours *in vitro* stimulation, SMARTA cells were transferred into 6-well plates in D-10 with 10 ng/ml hIL-2 for two days. One day prior to cell sorting reporter expressing cells (FACSAria, BD Biosciences) for transfer, culture media was replaced with D-10 with 2 ng/ml hIL-7. Detailed information is described elsewhere^[@R50]^.

Cell sorting {#S18}
------------

All the cell sorting was done on a FACSAria (BD Biosciences). For RNA-seq analyses, early T~FH~ (IL-2Rα^−^Blimp1-YFP^−^) or early T~H~1 (IL-2Rα^+^Blimp1-YFP^+^) SMARTA cells, or CXCR5^−^ (T~H~1), PD1^lo^CXCR5^+^ (T~FH~), and PD1^hi^CXCR5^+^ (GC T~FH~) subsets among activated GFP^+^CD4^+^ splenic T cells of *Lef1*^−/−^*Tcf7*^−/−^ or control mice were sorted on day 3 after LCMV infection or on day 8 after vaccinia virus infection, respectively. GFP-RV^+^ or *Lef1*-RV^+^ SMARTA cells were sorted as SLAM^hi^CXCR5^lo^ (T~H~1) or SLAM^lo^CXCR5^hi^ (T~FH~) cells on day 4 after LCMV infection. For ChIP analysis, CXCR5^−^ (T~H~1) and CXCR5^+^ (T~FH~) cells were sorted from activated CD4^+^ splenic T cells on day 8 after vaccinia virus infection. Also, CD44^lo^CD62L^hi^ naïve CD4^+^ T cells were sorted from WT or *Tcf7*^−/−^ (*Cd4*-Cre*Tcf7*^fl/fl^).

Retrovirus production and cell transfers {#S19}
----------------------------------------

Murine *Lef1* cDNA (clone ID 6401514, Open Biosystems) was cloned into expressing retroviral vector (pMIG-GFP). *Lef1* shRNA sequence (Transomic) was cloned into pLMPd-Ametrine vector, as reported^[@R26],\ [@R31]^. Virions were obtained from the Plat-E cells as described^[@R50]^. Briefly, culture supernatants were collected 24 and 48 hours after transfection, filtered through 0.45 µm syringe filter, and saved at 4°C until used for transductions.

Naïve or retrovirally transduced SMARTA cells were transferred into mice intravenously via retro-orbital sinus. When using transduced SMARTA cells, 100% of transferred cells were transduced (Ametrine^+^CD45.1^+^). Cell transfer numbers are 4--5 × 10^5^, 2 × 10^5^, and 5 × 10^3^ SMARTA cells were day 3, 4, and 8 experiments, respectively.

*In vitro* activation of CD4^+^ T cells {#S20}
---------------------------------------

Naïve SMARTA cells were negatively isolated by using CD4^+^ T cell isolation kit (Miltenyi or StemCell). 2 × 10^6^ SMARTA cells were seeded on 24 well plates coated with 8 µg/mL αCD3 (clone 17A2, BioXcell) and αCD28 (clone 37.51, BioXcell). For T~H~1polarization, Smarta cells were given with 20 µg/mL of αIL-4 (clone 11B11, BioXcell) and αTGF-β (clone 1D11, BioXcell) and 20 ng/mL of rmIL-12 (Peprotech). For IL-6 condition, 10 µg/mL of αIFN-γ (clone XMG1.2, BioXcell) and αIL-12 (clone R1-5D9, BioXcell) and 20 ng/mL of rmIL-6 (Peprotech) were added in culture media.

Quantitative RT-PCR {#S21}
-------------------

Total RNA from the sorted cells was extracted, reverse-transcribed, and quantitative PCR were performed as described^[@R16]^.

RNA-Seq and transcriptome analysis (Xue Group) {#S22}
----------------------------------------------

Total RNA was extracted from the sorted PD-1^+^CXCR5^+^ cells from *Tcf7*^−/−^*Lef1*^−/−^ or control mice, and two biological replicates were obtained for each genotype. cDNA synthesis and amplification were performed using SMARTer Ultra Low Input RNA Kit (Clontech) starting with 10 ng of total RNA per sample following manufacturer's instructions. cDNA was fragmented with Q800R sonicator (Qsonica) and used as input for NEBNext Ultra DNA Library Preparation Kit (NEB). Libraries were sequenced on Illumina's HiSeq2000 in single read mode with the read length of 50 nucleotides producing 60--70 million reads per sample. Sequence data in fastq format were generated using CASAVA 1.8.2 processing pipeline from Illumina.

The sequencing quality of RNA-Seq libraries was assessed by FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>, v0.10.1). Because of biased GC content in the 5' end, the first 12 bases of each read in all 4 samples were trimmed off. RNA-Seq data reproducibility was evaluated by computing Pearson's correlation of FPKM values for all genes between biological replicates. The Pearson's correlation coefficient between the two biological replicates was 0.937 for the control samples and 0.986 for the *Tcf7*^−/−^ *Lef1*^−/−^ samples, indicating strong reproducibility.

The RNA-Seq libraries were then processed by RSEM (v1.2.19) to estimate expression levels of all genes. The expression level of a gene is expressed as a gene-level FPKM (Fragments Per Kilobase of transcripts per Million mapped reads) value. EBSeq (v1.5.4), as an integral component of RSEM package, was used to identify differentially expressed genes. UCSC genes for mouse mm9 from iGenome (<http://support.illumina.com/sequencing/sequencing_software/igenome.html>) were used for gene annotation. The RNA-seq data are deposited at the Gene Expression Omnibus under accession number GSE66781.

RNA-Seq and transcriptome analysis (Crotty Group) {#S23}
-------------------------------------------------

Total RNA was extracted from cells stored in Trizol using the miRNeasy Mini Kit (Qiagen 217004). \[1\] For RNA-seq analysis for early T~FH~ and T~H~1 cells: poly(A) RNA was isolated using the Poly(A) Purist MAG kit (Ambion AM1922) from 200 ng total RNA of each sample. Resulting poly(A) RNA was then fragmented and prepared, according to the manufacturer's instructions (ABI 4452437 Rev B), into barcoded, strand-specific libraries using The SOLiD Total RNA-Seq Kit (ABI 4445374). Following library preparation, 15 ng of each library was converted into SOLiD Wildfire compatible fragments using the 5500 W Conversion Primer Kit (Life Technologies) and 5 rounds of PCR. Libraries were then pooled at equimolar concentrations using Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies) and sequenced on a Life Technologies 5500XL W Genetic Analyzer. SOLiD 5500-2 sequencing outcomes were converted from color space to nucleotide space by using Galaxy solid2fastq script. \[2\] For RNA-seq analysis for GFP-RV^+^ or *Lef1*-RV^+^ SMARTA cells obtained 4 days after LCMV infection: 500 ng of each sample's total RNA was then prepared into mRNA libraries, according to manufacturer's instructions (Illumina, RS-122-2103). The resulting libraries were deep sequenced on the Illumina 2500 in Rapid Run Mode, using single-end reads with lengths of 50 nucleotides (\> 24 million reads per condition). The single-end reads that passed Illumina filters were filtered for reads aligning to tRNA, rRNA, adapter sequences, and spike-in controls.

The reads were then aligned to UCSC mm9 reference genome using TopHat (v 1.4.1). DUST scores were calculated with PRINSEQ Lite (v 0.20.3) and low-complexity reads (DUST \> 4) were removed from the BAM files. The alignment results were parsed via the SAMtools to generate SAM files. Read counts to each genomic feature were obtained with the htseq-count program (v 0.6.0) using the "union" option. After removing absent features (zero counts in all samples), the raw counts were then imported to R/Bioconductor package DESeq2 to identify differentially expressed genes among samples. DESeq2 normalizes counts by dividing each column of the count table (samples) by the size factor of this column. The size factor is calculated by dividing the samples by geometric means of the genes. This brings the count values to a common scale suitable for comparison. P-values for differential expression are calculated using binomial test for differences between the base means of two conditions. These p-values are then adjusted for multiple test correction using Benjamini Hochberg algorithm to control the false discovery rate. We considered genes differentially expressed between two groups of samples when the DESeq2 analysis resulted in an adjusted P-value of \<0.05 and the fold-change in gene expression was 1.5-fold. Cluster analyses including principal component analysis (PCA) and hierarchical clustering were performed using standard algorithms and metrics. Hierarchical clustering was performed using complete linkage with Euclidean metric. RNA-seq data are deposited at the Gene Expression Omnibus under accession number GSE67336.

Heatmaps {#S24}
--------

Heatmaps were generated with normalized data of RNA-seq analyses for early T~FH~/T~H~1 cells and for GFP-RV^+^/Lef1-RV^+^ T~FH~/T~H~1 cells. Microarray analysis used published T~H~1, T~FH~ and GC T~FH~ cell sets (GSE21380, ref. ^[@R51]^) using the GenePattern software suite ([genepattern.broadinstitute.org](http://genepattern.broadinstitute.org)).

GSEA analysis {#S25}
-------------

GSEA analysis was performed using the GSEA software from the Broad Institute. T~FH~ and GC T~FH~ gene sets were generated in-house with genes that were expressed in T~FH~ (PD1^lo^CXCR5^+^) and GC T~FH~ (PD1^hi^CXCR5^+^) by more than 2-fold in comparison to T~H~1 (PD1^−^CXCR5^−^) cells, respectively (data obtained from GSE21380). Enrichment of genes, which were upregulated in *Lef1*-RV^+^ Th1 cells in comparison to GFP-RV^+^ T~H~1 cells by more than 1.2-fold, was then ranked by the Diff_of_Classes.

Chromatin immunoprecipitation (ChIP) {#S26}
------------------------------------

Sorted CD4^+^ T cells were cross-linked with 1% formaldehyde in medium for 5 minutes, processed using truChIP Chromatin Shearing Reagent Kit (Covaris), and sonicated for 5 minutes on Covaris S2 ultrasonicator. The sheared chromatin was immunoprecipitated with anti-TCF-1 (C46C7, Cell Signaling Technologies) or control rabbit IgG and washed as previously described. The immunoprecipitated DNA segments were used for PCR quantification. For calculation of enriched TCF-1 binding in a given cell type, each TCF-1 ChIP sample was first normalized to corresponding IgG ChIP sample, and the signal at a target region was then normalized to that at the *Hprt* promoter region.

Statistical analysis {#S27}
--------------------

Data sets were analyzed with the Student's *t*-test with a two-tailed distribution assuming equal sample variance.
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![*Lef1* expression is associated with T~FH~ cells and regulates early T~FH~ differentiation\
**(a)** RNA-seq analysis of early T~FH~ (IL-2Rα^−^Blimp1-YFP^−^) versus T~H~1 (IL-2Rα^+^Blimp1-YFP^+^) CD45.1^+^ Blimp1-YFP SMARTA cells isolated from B6 mice 3 d after SMARTA cell transfer and LCMV infection (left panels), and that of T~H~1 (CXCR5^−^), T~FH~ (PD-1^lo^CXCR5^+^), and GC T~FH~ (PD-1^hi^CXCR5^+^) sorted 8 d after LCMV from CD45.2^+^ B6 mice (right panels). Heatmaps of selected genes of interest are shown. **(b)** Scatter plot of genes showing ≥ \|1.5 fold\| differential expression in early T~FH~ in comparison to T~H~1 cells. Select genes of interest are marked. **(c)** Immunoblot of LEF-1 (two isoforms) and β-actin from sh*Ctrl^+^* and sh*Lef1^+^* SMARTA cells. **(d-f)** Analysis of sh*Ctrl^+^* or sh*Lef1^+^* CD45.1^+^ SMARTA cells (Ametrine^+^CD45.1^+^CD4^+^CD19^−^), three days after transfer of shRNA-RV-infected SMARTA cells into B6 mice and LCMV infection. **(d)** shRNA^+^ SMARTA cell frequency among total CD4^+^ T cells. **(e-f)** Phenotyping of sh*Ctrl^+^* and sh*Lef1^+^* SMARTA cells. (**e**) Bcl6^+^CXCR5^+^ T~FH~ cells. **(f)** IL-2Rα^−^CXCR5^+^ T~FH~ cells. Quantitation shown as % of SMARTA cells (mean ± s.e.m.). Data are a composite of two independent experiments (n = 7 per group). \* *P* \< 0.05, \*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f1){#F1}

![LEF-1-dependent T~FH~ differentiation supports germinal center responses\
(**a-e**) Frequencies and phenotypes of sh*Ctrl*^+^ or sh*Lef1*^+^ CD45.1^+^ SMARTA cells assessed by flow cytometry at 8 d after SMARTA cell transfer into B6 mice and LCMV infection. **(a)** Abundance of shRNA^+^ SMARTA cells (Ametrine^+^CD45.1^+^CD4^+^CD19^−^) among total CD4^+^ T cells. **(b)** Frequency of SLAM^lo^CXCR5^+^ T~FH~ cells. Quantitation shown as % of SMARTA cells. **(c)** Expression of CXCR5 on sh*Ctrl*^+^ (blue) and sh*Lef1*^+^ (red) SMARTA cells. **(d-e)** Frequencies of sh*Ctrl^+^* and sh*Lef1^+^* SMARTA GC T~FH~ cells among SMARTA cells phenotyped as PSGL-1^lo^CXCR5^+^**(d)** and Bcl6^hi^CXCR5^+^ (**e**). **(f)** Abundance of GC B cells (Bcl6^+^CD19^+^) among total B cells. Data are representative of two independent experiments (n = 4--5 per group, mean ± s.e.m.). \* *P* \< 0.05 (Student's *t*-test).](nihms700724f2){#F2}

![Genetic ablation of LEF-1 impairs GC T~FH~ differentiation\
(**a-c**) Flow cytometry of T~FH~ and GC T~FH~ cells in spleens of *Lef1*^−/−^ mice and littermate controls infecte*d w*ith vaccinia virus for 8 days. Plots are gated on CD44^hi^CD62L^lo^GFP^+^CD4^+^ T cells. **(a)** SLAM^lo^CXCR5^+^ T~FH~ cells. (**b-c**) Abundance of GC T~FH~ cells phenotyped as Bcl6^+^CXCR5^+^ (**b**) and PD-1^hi^CXCR5^+^**(c)**. Cumulative data from four independent experiments are shown (mean ± s.d.). \* *P* \< 0.01, \*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f3){#F3}

![Both TCF-1 and LEF-1 contribute to regulation of T~FH~ differentiation and B cell responses\
**(a)** Flow cytometry of *Tcf7*-GFP expression in SMARTA CD4^+^ T cells (CD45.2^+^CD4^+^) at 8 d after *Tcf7*^GFP/+^ SMARTA cell transfer into CD45.1^+^ recipients and LCMV infection. Gated populations of T~H~1 (CXCR5^−^SLAM^hi^) and T~FH~ (CXCR5^+^SLAM^lo^) cells were analyzed for *Tcf7*-GFP expression. Numbers indicate percent *Tcf7*-GFP^+^ cells. Data are representative of ≥ 2 experiments. **(b-f)** Flow cytometry of *Tcf7*^−/−^*Lef1*^−/−^*Tcf7*^−/−^, and littermate controls 8 d after infection *i.v*. with vaccinia virus. **(b-d)** Abundance of SLAM^lo^CXCR5^+^ T~FH~ cells **(b)**, Bcl6^+^CXCR5^+^ GC T~FH~ cells **(c)**, and PD-1^hi^CXCR5^+^ GC T~FH~ cells **(d)** gated on CD44^hi^CD62L^−^GFP^+^CD4^+^ T cells in spleen. (**e-f**) Abundance of GL7^+^Fas^+^ GC B cells **(e)** and IgD^lo^CD138^+^ plasma cells **(f)** in the same animals (mean ± s.d.). Cumulative data from ≥ 3 experiments are shown. \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f4){#F4}

![Enhanced *Lef1* expression leads to augmented T~FH~ differentiation\
**(a)** Expression of LEF-1 in GFP-RV^+^ (blue) and *Lef1*-RV^+^ (red) SMARTA cells assessed by flow cytometry. **(b-g)** Frequencies and phenotypes of GFP-RV^+^ or *Lef1*-RV^+^ SMARTA cells (CD45.1^+^CD4^+^CD19^−^) assessed by flow cytometry at 8 d after SMARTA cell transfer into B6 mice (CD45.2^+^) and LCMV infection. **(b)** Abundance of RV^+^ SMARTA cell (GFP^+^CD45.1^+^CD4^+^CD19^−^) among total CD4^+^ T cells. **(c)** Abundance of SLAM^lo^CXCR5^+^ T~FH~ cells among RV^+^ SMARTA cells. **(d-e)** Expression of canonical T~FH~ markers CXCR5 **(d)** and PD-1 **(e)** on CXCR5^−^ T~H~1 and CXCR5^+^ T~FH~ cells by *Lef1*-RV^+^ and GFP-RV^+^ cells, normalized to the mean MFI per group (mean ± s.e.m.). **(f-g)** Abundance of GC T~FH~ cells phenotyped as PSGL-1^lo^CXCR5^+^**(f)** and PD-1^hi^CXCR5^+^**(e)** of RV^+^ SMARTA cells. Data are a composite of two independent experiments (n = 9 per group). \* *P* \< 0.01, \*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f5){#F5}

![LEF-1 regulates expression of IL-6 receptor chains and ICOS\
**(a-b)** RNA-seq analysis of GFP-RV^+^ and *Lef1*-RV^+^ SMARTA cells (CD45.1^+^CD4^+^CD19^−^) sorted into CXCR5^+^ T~FH~ or CXCR5^−^ T~H~1 populations isolated from B6 mice 4 d after SMARTA cell transfer and LCMV infection. **(a)** GSEA enrichment analysis showing enrichment of T~FH~ and GC T~FH~ gene signatures in *Lef1*-RV^+^ T~H~1 cells compared to GFP-RV^+^ T~H~1 cells. **(b)** Heat map of selected genes upregulated in *Lef1*-RV^+^ T~H~1 cells compared to GFP-RV^+^ T~H~1 cells. **(c-h)** Flow cytometry of GFP-RV^+^ or *Lef1*-RV^+^ SMARTA cells (CD45.1^+^CD4^+^CD19) assessed at 3 d after SMARTA cell transfer into B6 mice (CD45.2^+^) and LCMV infection. (**c-d**) Expression of IL6Rα**(c)** and gp130 **(d)** on RV^+^ SMARTA cells. **(e-f)** Comparative expression of IL-6Rα (**e**) and gp130 (**f**) GFP-RV^+^ (red) and *Lef1*-RV^+^ (blue) T~H~1 and T~FH~ cells. (**g-h**) Abundance of ICOS on total RV^+^ SMARTA cells **(g)**, CXCR5^+^ T~FH~ and CXCR5^−^ T~H~1 cell subpopulations **(h)** in the same animal (mean ± s.e.m.). Data are a composite of three independent experiments (n = 10--14 per group). \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f6){#F6}

![LEF-1 and TCF-1-dependent transcriptional regulation of T~FH~-related genes\
**(a)** RNA-seq analysis of PD-1^hi^CXCR5^+^ GC T~FH~ cells sorted from spleens of *Lef1*^−/−^*Tcf7*^−/−^ and littermate controls 8 d after vaccinia virus infection. Green lines mark mean gene expression of ≥ \|1.5 fold\| differences. Select genes of interest are marked. **(b)** Heatmap of selected differentially regulated genes between control and *Lef1*^−/−^*Tcf7*^−/−^ GC T~FH~ cells. **(c-e)** Flow cytometry of *Lef1*^−/−^*Tcf7*^−/−^ and littermate controls 8 d after infection *i.v*. with vaccinia virus. CXCR5^+^ T~FH~ and CXCR5^−^ T~H~1 cells were analyzed for gp130 **(c)**, ICOS **(d)**, and IL-6Rα **(e)** expression (mean ± s.d.). Bar graphs are normalized to the mean MFI on control T~FH~ cells. Data are a composite of 4 independent experiments (n = 5--9 per group). **(f)** Gene expression of *Ascl2* and *Prdm1* was determined by quantitative RT-PCR in CXCR5^−^ T~H~1, PD-1^lo^CXCR5^+^ T~FH~, and PD-1^hi^CXCR5^+^ GC T~FH~ cells sorted from *Lef1*^−/−^*Tcf7*^−/−^ and littermate controls 8 d after infection *i.v*. with vaccinia virus. Data are from 2 experiments with each sample measured in duplicate and normalized to control T~FH~ cells. ND, not reliably detected. \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f7){#F7}

![TCF-1 binds to key T~FH~-associated genes in T~FH~ cells\
**(a-d)** ChIP assays using anti-TCF-1 antibody or control IgG were performed on naive control CD4^+^ T cells (CD44^lo^CD62L^+^CD4^+^); naive *Tcf7*^−/−^ CD4^+^ T cells (GFP^+^CD44^lo^CD62L^+^CD4^+^); WT T~FH~ cells (CXCR5^+^CD44^hi^CD62L^−^CD4^+^); and WT T~H~1 cells (CXCR5^−^CD44^hi^CD62L^−^CD4^+^). T~FH~ and T~H~1 cells were sorted from B6 mice 8 d after vaccinia virus infection. Quantitation of enriched TCF-1 binding was done at the positive control *Axin2* gene **(a)**, the TSS of the *Il6ra* and *Il6st* genes **(b)**, the TSS and a −2.8 kb upstream regulatory region of the *Bcl6* gene **(c)**, and the TSS of *Ascl2* and intron 3 of *Prdm1* **(d)**, and data are means ± s.d. from 3 independent experiments. \* *P* \< 0.05, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001 (Student's *t*-test).](nihms700724f8){#F8}
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